About Sumitomo Dainippon Pharma
Sumitomo Dainippon Pharma is a company based in Osaka (Japan) founded in 1897. Sumitomo Dainippon Pharma has completed 4 acquisitions, including Boston Biomedical, Sepracor and Sunovion. Sumitomo Dainippon Pharma operates in a competitive market with competitors including Annexon, Syndax, Clovis Oncology, Auron Therapeutics and C4X Discovery, among others.
- Headquarter Osaka, Japan
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
-
Investments & Acquisitions
Boston Biomedical
& 3 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Sumitomo Dainippon Pharma
Unlock access to complete
Unlock access to complete
Funding Insights of Sumitomo Dainippon Pharma
Detailed funding history for Sumitomo Dainippon Pharma
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sumitomo Dainippon Pharma
Sumitomo Dainippon Pharma has strategically engaged in corporate development activities, having acquired 4 companies. Notable acquisitions include Boston Biomedical, Sepracor and Sunovion.
Investment portfolio details for Sumitomo Dainippon Pharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapeutics for cancer and blood disorders are developed.
|
Locked | Locked | 2011 | Locked | |
|
Develops novel therapeutics for treatment of cancer
|
Locked | Locked | 2006 | Locked | |
|
Pharmaceutical products for respiratory and CNS disorders are developed.
|
Locked | Locked | 1984 | Locked |
Complete acquisition details for Sumitomo Dainippon Pharma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Sumitomo Dainippon Pharma
Detailed financials for Sumitomo Dainippon Pharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sumitomo Dainippon Pharma Comparisons
Peer comparison for Sumitomo Dainippon Pharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sumitomo Dainippon Pharma
Sumitomo Dainippon Pharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Syndax, Clovis Oncology, Auron Therapeutics and C4X Discovery, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Develops innovative immunotherapy drugs for cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of cancer therapeutics for the treatment of blood cancer
|
|
| Locked | Locked | Locked |
Developer of optimized drug discovery and design services
|
|
| Locked | Locked | Locked |
Personalized cell-based autologous therapies for anti-tumor applications are provided.
|
Detailed competitors of Sumitomo Dainippon Pharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sumitomo Dainippon Pharma
Complete news archive for Sumitomo Dainippon Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sumitomo Dainippon Pharma
Sumitomo Dainippon Pharma was founded in 1897.
Sumitomo Dainippon Pharma is headquartered in Osaka, Japan. It is registered at Osaka, Osaka Prefecture, Japan.
Sumitomo Dainippon Pharma was founded in 1897 and is headquartered in Osaka, Japan. Operations focus on the pharmaceutical sector, where 11 products are developed for therapeutic areas including hypertension, Parkinsons disease, and antifungal treatments. Additional activities encompass the production of food ingredients, food additives, and veterinary products, supporting diverse markets in healthcare and nutrition.
Sumitomo Dainippon Pharma's top competitors include Syndax, iTeos Therapeutics and Annexon.
Sumitomo Dainippon Pharma has made 4 acquisitions, including Boston Biomedical, Sepracor, and Sunovion.